DongKook Pharmaceutical Co. Ltd (086450) — Cash Flow-to-Debt Ratio
DongKook Pharmaceutical Co. Ltd (086450) has a Cash Flow-to-Debt Ratio of 0.07x as of March 2026, meaning its operating cash flow of ₩22.58 Billion could theoretically repay 0% of its total liabilities (₩310.75 Billion) in one year. Explore 086450 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
DongKook Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for DongKook Pharmaceutical Co. Ltd across 13 annual periods. Also explore DongKook Pharmaceutical Co. Ltd asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for DongKook Pharmaceutical Co. Ltd (2013–2025)
Year-by-year debt coverage analysis for DongKook Pharmaceutical Co. Ltd. For market capitalisation and broader financial context, see DongKook Pharmaceutical Co. Ltd (086450) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | ₩68.76 Billion | ₩299.16 Billion | ▼ -17.2% |
| 2024 | 0.28x | ₩76.09 Billion | ₩274.19 Billion | ▲ +74.9% |
| 2023 | 0.16x | ₩41.79 Billion | ₩263.36 Billion | ▲ +3.3% |
| 2022 | 0.15x | ₩40.91 Billion | ₩266.39 Billion | ▲ +1.6% |
| 2021 | 0.15x | ₩44.65 Billion | ₩295.51 Billion | ▼ -35.6% |
| 2020 | 0.23x | ₩59.11 Billion | ₩251.80 Billion | ▼ -38.7% |
| 2019 | 0.38x | ₩69.48 Billion | ₩181.51 Billion | ▲ +92.8% |
| 2018 | 0.20x | ₩33.21 Billion | ₩167.22 Billion | ▼ -24.2% |
| 2017 | 0.26x | ₩28.66 Billion | ₩109.37 Billion | ▼ -41.6% |
| 2016 | 0.45x | ₩39.41 Billion | ₩87.78 Billion | ▲ +24.4% |
| 2015 | 0.36x | ₩27.14 Billion | ₩75.18 Billion | ▲ +7.3% |
| 2014 | 0.34x | ₩22.74 Billion | ₩67.60 Billion | ▼ -5.1% |
| 2013 | 0.35x | ₩19.86 Billion | ₩56.02 Billion | — |